Altimmune Bets Big on PEMB as Phase III Nears

Altimmune ((ALT)) has held its Q4 earnings call. Read on for the main highlights of the call.

Altimmune’s latest earnings call struck an upbeat tone, with management leaning on robust Phase II liver data, a coveted FDA Breakthrough Therapy designation, and a fortified balance sheet that extends cash runway into 2028. Risks around higher spending, biopsy‑heavy Phase III design, and intense competition were acknowledged, but executives framed these as execution challenges rather than strategic threats.

Phase II MATCH and IMPACT Data Underscore PEMB’s Potential

Altimmune highlighted strong Phase II results for PEMB, showing early NASH resolution at 24 weeks and clear antifibrotic activity by week 48, with a supportive dose response. Noninvasive markers such as ELF, liver stiffness, ALT, and cT1 all improved, and the 1.8 mg dose delivered 7.5% average weight loss at 48 weeks without an apparent plateau, reinforcing confidence in advancing this dose and testing 2.4 mg.

Tolerability Profile Supports Broader Use

Management emphasized that PEMB’s tolerability could be a key commercial differentiator, noting limited gastrointestinal adverse events and low discontinuation rates in Phase II despite the lack of dose titration. Most GI events clustered in the first one to two months, and the company plans a simple one‑ or two‑step titration in Phase III to further reduce drop‑outs and support long‑term adherence.

Regulatory Momentum with Breakthrough Status

PEMB has secured FDA Breakthrough Therapy designation in NASH, signaling regulatory recognition of its potential in a high‑need indication. End‑of‑Phase II meeting minutes confirmed alignment with the FDA on key Phase III elements, including population, endpoints, and powering, and the pivotal program will use biopsy‑based endpoints supported by AI‑assisted histologic assessment.

Ambitious Phase III Design Targets Accelerated Approval

The planned Phase III program will enroll roughly 1,800 patients, anchored by about 990 biopsy‑confirmed F2/F3 NASH patients split evenly across placebo, 1.8 mg, and 2.4 mg PEMB arms. This biopsy cohort will be powered above 90% for co‑primary 52‑week endpoints of NASH resolution without worsening of fibrosis or fibrosis improvement without worsening of NASH, supported by a separate ~800‑patient NIT cohort.

Market Research Points to Strong Prescriber Interest

Altimmune’s market research across 75 U.S. healthcare providers suggests PEMB could secure meaningful share in the NASH treatment landscape if approved. Over 70% of respondents reported a high or very high likelihood to prescribe, with projected use in around 43% of F2 and 51% of F3 patients, and more than 80% positioning PEMB as a first‑ or second‑line therapy based on tolerability and lean‑mass‑sparing weight loss.

Pipeline Expansion into Alcohol‑Related Liver Disease

Beyond NASH, Altimmune is extending PEMB into alcohol‑associated indications, aiming to broaden the asset’s liver franchise potential. Enrollment in the Phase II RECLAIM trial in alcohol use disorder finished ahead of schedule, with top‑line data expected in the third quarter of 2026, while the RESTORE study in alcohol‑related liver disease is enrolling and targeted to complete in 2026.

Balance Sheet Strength Provides Multi‑Year Runway

Altimmune exited the year with about $274 million in cash, which, combined with a January financing package, lifts pro forma liquidity to roughly $340 million. Net proceeds recognized in 2025 totaled about $208 million across equity and a loan facility, giving the company sufficient capital to fund its expansive Phase III plans and broader development program into 2028.

Scaling Up Operations for Global Late‑Stage Execution

To prepare for the demands of a large global trial, management has been building out its late‑stage development and commercial infrastructure. The company reported advanced protocol work and regulatory planning and is targeting a global footprint spanning the Americas, Europe, and Asia, positioning Altimmune to handle complex logistics, including biopsy management and AI‑based pathology.

Higher Net Loss Reflects Investment Phase

Altimmune reported a full‑year 2025 net loss of $27.4 million, or $0.27 per share, compared with $23.2 million, or $0.33 per share, in 2024, an increase of roughly 18%. Management framed the wider loss as a function of increased R&D and corporate spending tied to the transition into late‑stage development rather than a structural deterioration in the business model.

G&A Surge Driven by One‑Off and Noncash Items

General and administrative expenses more than doubled in the fourth quarter of 2025 to $10.5 million from $5.1 million a year earlier, a jump attributed largely to nonrecurring and equity‑based charges. A one‑time $2.6 million executive transition cost and higher stock‑based compensation, which rose to $3.6 million from $1.8 million, accounted for much of the spike.

Cash Operating Costs Rising with Phase III Ramp

Cash operating expenses for 2025 were about $67.5 million excluding $16 million of noncash compensation, underscoring growing investment ahead of Phase III initiation. Management signaled that cash use will trend higher in 2026 as the pivotal NASH program launches, highlighting the need for disciplined spending even with a multi‑year cash cushion.

Biopsy Dependence Adds Complexity and Cost

The company noted that the FDA currently views it as premature to rely on noninvasive tests as registrational endpoints in NASH, reinforcing biopsy‑based readouts as the primary approval path. This regulatory stance means Altimmune must manage a more complex and costly pivotal trial, with extensive biopsy logistics and AI‑enabled pathology workstreams layered onto global enrollment.

Execution Risks in ALD and Global Recruitment

Management flagged enrollment in alcohol‑related liver disease as inherently slower and more challenging than in alcohol use disorder, which could pressure timelines. The global Phase III NASH trial also carries operational risk, including coordinating biopsy collection, validating pathologist panels and AI tools, and enrolling large patient numbers across multiple regions.

Competitive Landscape for Dual‑Agonists Remains Fluid

Altimmune operates in a crowded dual‑agonist field, and the company acknowledged that competing programs’ efficacy and tolerability profiles could affect PEMB’s ultimate positioning. The team is betting on PEMB’s balanced glucagon/GLP‑1 activity, tolerability, and body‑composition profile, but comparative data from peers could reshape expectations on pricing, share, and adoption.

Upside Hinges on 2.4 mg Dose Differentiation

The Phase III trial is powered on the 1.8 mg dose, with the higher 2.4 mg arm viewed as an opportunity for additional upside rather than a necessity. If the 2.4 mg dose fails to deliver clear incremental benefits on weight loss or liver endpoints, PEMB’s differentiation may rest primarily on its base dose profile rather than step‑up efficacy.

Guidance and Key Milestones Ahead

Altimmune guided to initiating its pivotal global Phase III NASH trial in 2026, enrolling roughly 1,800 patients across biopsy and NIT cohorts with a titration scheme starting at 1.2 mg and stepping to 1.8 mg or 2.4 mg. The trial is designed to support accelerated approval using AI‑assisted histology, while Phase II RECLAIM top‑line data in AUD and completion of ALD enrollment, both expected in 2026, add additional catalysts alongside a projected cash runway into 2028.

Altimmune’s call painted the picture of a company leaning into late‑stage risk with notable clinical and regulatory momentum, backed by ample capital to execute its plan. Investors will be watching closely as the pivotal NASH program launches and alcohol‑related liver studies mature, testing whether PEMB’s promising Phase II profile can translate into a commercially meaningful franchise.